# Juhaeri Juhaeri

List of Publications by Year
in descending order

| | | 471509 | 477307 |
|---|---|---|---|
| 40 papers | 954 citations | 17 h-index | 29 g-index |
| 41 all docs | 41 docs citations | 41 times ranked | 1355 citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998â€"2013: A Retrospective Cohort Study. Diabetes Care, 2018, 41, 1870-1877. | 8.6 | 101 |
| 2 | Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today, 2019, 24, 1324-1331. | 6.4 | 90 |
| 3 | Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. Drug Discovery Today, 2019, 24, 57-68. | 6.4 | 69 |
| 4 | Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiology and Drug Safety, 2003, 12, 611-616. | 1.9 | 53 |
| 5 | Recommendations for benefitâ€"risk assessment methodologies and visual representations. Pharmacoepidemiology and Drug Safety, 2016, 25, 251-262. | 1.9 | 51 |
| 6 | Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998â€"2013: A Retrospective Cohort Study. Diabetes Care, 2017, 40, 1651-1660. | 8.6 | 49 |
| 7 | Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. Frontiers in Pharmacology, 2019, 10, 1395. | 3.5 | 48 |
| 8 | Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. BMC Medical Informatics and Decision Making, 2019, 19, 189. | 3.0 | 36 |
| 9 | Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiology and Drug Safety, 2009, 18, 497-503. | 1.9 | 33 |
| 10 | Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. Journal of Allergy and Clinical Immunology, 2016, 138, 97-104.e7. | 2.9 | 28 |
| 11 | Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. BMC Medical Informatics and Decision Making, 2020, 20, 114. | 3.0 | 26 |
| 12 | Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiology and Drug Safety, 2003, 12, 693-697. | 1.9 | 25 |
| 13 | Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. Patient, 2019, 12, 513-526. | 2.7 | 24 |
| 14 | Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. BMC Nephrology, 2011, 12, 17. | 1.8 | 23 |
| 15 | Benefitâ€"Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. Pharmacoepidemiology and Drug Safety, 2015, 24, 1233-1240. | 1.9 | 23 |
| 16 | Benefitâ€"risk evaluation: the past, present and future. Therapeutic Advances in Drug Safety, 2019, 10, 204209861987118. | 2.4 | 22 |
| 17 | Web-Based Signal Detection Using Medical Forums Data in France: Comparative Analysis. Journal of Medical Internet Research, 2018, 20, e10466. | 4.3 | 22 |
| 18 | Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Therapeutic Advances in Drug Safety, 2019, 10, 204209861986474. | 2.4 | 21 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | Benefit–risk assessment in a post–market setting: a case study integrating real–life experience into benefit–risk methodology. Pharmacoepidemiology and Drug Safety, 2014, 23, 974-983. | 1.9 | 17 |
| 20 | The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program – Current Status and Future Direction. Clinical Therapeutics, 2016, 38, 2526-2532. | 2.5 | 17 |
| 21 | HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. Journal of Diabetes and Its Complications, 2018, 32, 203-209. | 2.3 | 17 |
| 22 | Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. Cancer Epidemiology, 2015, 39, 242-249. | 1.9 | 16 |
| 23 | Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. Frontiers in Pharmacology, 2019, 10, 1009. | 3.5 | 16 |
| 24 | Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1340-1347. | 2.3 | 15 |
| 25 | Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS. Drug Safety, 2017, 40, 399-408. | 3.2 | 13 |
| 26 | Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. Journal of Atrial Fibrillation, 2013, 6, 890. | 0.5 | 13 |
| 27 | The Incidence Rate of Seizures in Relation to BMI in UK Adults. Obesity, 2008, 16, 2126-2132. | 3.0 | 10 |
| 28 | Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data. Pharmacoepidemiology and Drug Safety, 2021, 30, 610-618. | 1.9 | 10 |
| 29 | The risk of acute liver injury associated with the use of antibiotics—evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project.. Pharmacoepidemiology and Drug Safety, 2016, 25, 47-55. | 1.9 | 9 |
| 30 | Comparison of text processing methods in social media–based signal detection. Pharmacoepidemiology and Drug Safety, 2019, 28, 1309-1317. | 1.9 | 9 |
| 31 | Age- and sex-specific incidence of non-traumatic lower limb amputation in patients with type 2 diabetes mellitus in a U.S. claims database. Diabetes Research and Clinical Practice, 2020, 169, 108452. | 2.8 | 9 |
| 32 | Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics. Clinical Therapeutics, 2018, 40, 450-455.e1. | 2.5 | 8 |
| 33 | Structured benefit–risk evaluation for medicinal products: review of quantitative benefit–risk assessment findings in the literature. Therapeutic Advances in Drug Safety, 2020, 11, 204209862097695. | 2.4 | 8 |
| 34 | Assessment of Dronedarone Utilization Using US Claims Databases. Clinical Therapeutics, 2014, 36, 264-272.e2. | 2.5 | 7 |
| 35 | Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database. Clinical Therapeutics, 2011, 33, 1483-1490.e3. | 2.5 | 6 |
| 36 | Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiology and Drug Safety, 2021, 30, 1353-1359. | 1.9 | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | Incidence of diabetic ketoacidosis and its trends in patients with type 1 diabetes mellitus identified using a U.S. claims database, 2007â€"2019. Journal of Diabetes and Its Complications, 2021, 35, 107932. | 2.3 | 4 |
| 38 | Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1989-1998. | 3.6 | 2 |
| 39 | Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedarone and Digoxin Using Real-World Data. Clinical Therapeutics, 2021, 43, 852-858.e2. | 2.5 | 0 |
| 40 | Abstract 18020: Identifying Hospitalizations Related to Heart Failure in Dronedarone Users Who Are Supplementary Medicare Beneficiaries. Circulation, 2014, 130, . | 1.6 | 0 |